Ultra- and Diafiltration Clear Leachables Effectively

Why It Matters

UF/DF is validated as a reliable mitigation strategy, giving biopharma developers quantitative confidence to satisfy regulators and protect product safety.

Key Takeaways

• UF/DF achieved >98% clearance for 24 of 28 test leachables
• Clearance remained consistent across three different protein processes
• Log P below 4 gave near‑perfect removal; >7 still >93% cleared
• OPLS regression predicts sieving coefficients from physicochemical properties

Pulse Analysis

Downstream purification has become a focal point for biopharma companies seeking to de‑risk biologics manufacturing. While ultrafiltration and diafiltration are routinely employed, hard data on their ability to strip small‑molecule leachables have been limited. This gap matters because extractables and leachables can compromise patient safety and trigger regulatory delays. The new research fills that void by systematically spiking 28 representative organics into three protein streams and tracking removal with high‑resolution mass spectrometry, providing the first broad, quantitative benchmark for UF/DF performance.

The study’s results are striking: 24 compounds showed greater than 98% clearance regardless of protein type or process parameters, indicating that UF/DF’s sieving behavior is remarkably stable. Lipophilicity emerged as the dominant predictor—compounds with Log P under 4 were essentially eliminated, while even those with Log P above 7 still cleared at rates above 93%. By applying orthogonal partial least squares (OPLS) regression, the team translated these observations into a predictive model that estimates sieving coefficients from molecular weight, polarizability, surface area, and Log P. This tool enables developers to forecast leachable removal without exhaustive bench testing, accelerating formulation design and risk assessment.

Regulators worldwide are tightening expectations around extractables and leachables, demanding clear evidence of mitigation strategies. The confirmation that UF/DF delivers high, reproducible clearance, coupled with a robust predictive framework, equips manufacturers with the data needed for regulatory submissions and for building safety cases early in development. As the industry moves toward more complex biologics and continuous processing, the ability to both measure and anticipate contaminant removal will be a competitive advantage, supporting faster time‑to‑market while safeguarding patient health.